Italfarmaco licenses JCR's Phase III Hunter syndrome therapy JR-141 across US, Europe and Latin America
Italfarmaco has licensed JCR Pharmaceuticals' Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America.
Italfarmaco receives exclusive development and commercialisation rights to the blood-brain-barrier-penetrating enzyme replacement therapy, which is already approved in Japan as IZCARGO.
JCR will retain manufacturing responsibility and receive upfront, milestone and royalty payments as well as supply revenue under the agreement.
Field | Content |
Article Type | Deals |
Companies | Italfarmaco; JCR Pharmaceuticals |
Deal Type | Exclusive regional licensing agreement |
Key Asset | JR-141 |
Approved Brand | IZCARGO |
Indication | Hunter syndrome |
Therapy Area | Rare disease; metabolic disease |
Technology/Modality | Blood-brain-barrier-penetrating enzyme replacement therapy |
Development Stage | Global Phase III |
Licensed Territories | United States; Europe; Latin America |
Existing Approval | Approved in Japan as IZCARGO |
Development Rights | Italfarmaco receives exclusive development rights in licensed territories |
Commercial Rights | Italfarmaco receives exclusive commercialisation rights in licensed territories |
Manufacturing Responsibility | JCR Pharmaceuticals retains manufacturing responsibility |
Financial Terms | Upfront, milestone and royalty payments plus supply revenue; amounts not disclosed |
What Happened | Italfarmaco licensed JR-141 from JCR Pharmaceuticals for development and commercialisation across the US, Europe and Latin America. |
Why It Matters | The agreement gives Italfarmaco access to a late-stage rare-disease therapy designed to cross the blood-brain barrier, addressing both systemic and neurological manifestations of Hunter syndrome. |
Supporting Context | JR-141 is already marketed in Japan as IZCARGO and is progressing through global Phase III development. |
Strategic Rationale | Italfarmaco gains a differentiated late-stage rare-disease asset while JCR expands JR-141's international reach through a regional commercial partner. |
Potential Impact | If approved, JR-141 could broaden treatment options for Hunter syndrome patients across major Western and Latin American markets. |
Key Takeaway | Italfarmaco has secured rights to Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America. |
What to Watch | Phase III results, regulatory submissions in licensed markets and timing of potential launches outside Japan. |
Primary Source | JCR Pharmaceuticals |
Relevant Date | 2 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare